SCHEMBL25545346

SCHEMBL25545346

CC(C)Cc1sc(Nc2ncc(-c3cccs3)cc2C(=O)O)nc1-c1cccs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ ALDH1A1 P00352 7/20 0.44
▸ KDM4E B2RXH2 5/20 0.44
▸ KMT2A Q03164 5/20 0.44
▸ MEN1 O00255 4/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ CACNA1B Q00975 2/20 0.44
▸ APBA1 Q02410 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ GAA P10253 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ FBP1 P09467 2/20 0.39
▸ RAD52 P43351 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ RXFP1 Q9HBX9 2/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544973 0.95 MAPT (0.45) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL25545380 0.94 MAPT (0.41) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL25545038 0.93 CDK2 (0.42) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL25545357 0.92 MAPT (0.40) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL27459004 0.91 MAPT (0.39) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL25545304 0.91 MAPT (0.39) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL25560844 0.91 MAPT (0.43) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL27459015 0.91 MAPT (0.39) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL23791997 0.91 MAPT (0.47) MAPTNPC1ALDH1A1KDM4EKMT2A
SCHEMBL25545309 0.91 DHODH (0.42) MAPTNPC1ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 MAPT 2231/4885NPC1 2317/4885ALDH1A1 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback